Table 5.
Percentages of P. aeruginosa isolates collected in ten Latin American countries as part of the ATLAS global surveillance program from 2017 to 2019 that were susceptible to ceftazidime-avibactam and comparator agents.
| Country | Antimicrobial agent | Phenotype/genotype | |||||
|---|---|---|---|---|---|---|---|
| (no. of isolates) | |||||||
| % Susceptible (CLSI) |
|||||||
| All isolates | Meropenem-NS | Meropenem-NS, MBL-, All | Meropenem-NS, MBL-, carbapenemase+ | Meropenem-NS, MBL-, carbapenemase- | Multidrug-resistant | ||
| Argentina | (308) | (85) | (80)a | (71) | |||
| Ceftazidime-avibactam | 97.4 | 91.8 | 97.5 | 88.7 | |||
| Ceftazidime | 75.0 | 36.5 | 38.8 | 16.9 | |||
| Cefepime | 73.7 | 30.6 | 32.5 | 7.0 | |||
| Piperacillin-tazobactam | 69.8 | 20.0 | 21.3 | 5.6 | |||
| Meropenem | 72.4 | 0 | 0 | 15.5 | |||
| Levofloxacin | 62.0 | 16.5 | 17.5 | 11.3 | |||
| Amikacin | 85.1 | 55.3 | 57.5 | 43.7 | |||
| Colistin | NA | NA | NA | NA | |||
| Brazil | (425) | (115) | (109)b | (70) | |||
| Ceftazidime-avibactam | 95.3 | 86.1 | 90.8 | 72.9 | |||
| Ceftazidime | 78.6 | 62.6 | 66.1 | 22.9 | |||
| Cefepime | 78.4 | 55.7 | 58.7 | 4.3 | |||
| Piperacillin-tazobactam | 73.6 | 47.8 | 50.5 | 5.7 | |||
| Meropenem | 72.9 | 0 | 0 | 30.0 | |||
| Levofloxacin | 69.2 | 34.8 | 36.7 | 15.7 | |||
| Amikacin | 90.8 | 78.3 | 80.7 | 50.0 | |||
| Colistin | NA | NA | NA | NA | |||
| Chile | (257) | (120) | (16) | (60) | (84) | ||
| Ceftazidime-avibactam | 77.4 | 51.7 | 75.0 | 78.3 | 42.9 | ||
| Ceftazidime | 58.0 | 18.3 | 0 | 36.7 | 1.2 | ||
| Cefepime | 60.3 | 21.7 | 0 | 38.3 | 1.2 | ||
| Piperacillin-tazobactam | 57.6 | 16.7 | 0 | 30.0 | 6.0 | ||
| Meropenem | 53.3 | 0 | 0 | 0 | 1.2 | ||
| Levofloxacin | 49.0 | 15.0 | 0 | 25.0 | 3.6 | ||
| Amikacin | 77.0 | 56.7 | 87.5 | 76.7 | 45.2 | ||
| Colistin | NA | NA | NA | NA | NA | ||
| Colombia | (384) | (124) | (26) | (68) | (86) | ||
| Ceftazidime-avibactam | 87.5 | 62.1 | 53.8 | 92.6 | 46.5 | ||
| Ceftazidime | 71.4 | 35.5 | 0 | 63.2 | 5.8 | ||
| Cefepime | 71.9 | 33.9 | 0 | 61.8 | 1.2 | ||
| Piperacillin-tazobactam | 69.3 | 29.0 | 0 | 50.0 | 5.8 | ||
| Meropenem | 67.7 | 0 | 0 | 0 | 10.5 | ||
| Levofloxacin | 67.2 | 26.6 | 19.2 | 39.7 | 19.8 | ||
| Amikacin | 85.9 | 60.5 | 30.8 | 92.6 | 45.3 | ||
| Colistin | NA | NA | NA | NA | NA | ||
| Costa Rica | (55) | (8) | (7)c | (4) | |||
| Ceftazidime-avibactam | 96.4 | 87.5 | 100 | 50.0 | |||
| Ceftazidime | 81.8 | 87.5 | 100 | 25.0 | |||
| Cefepime | 94.5 | 87.5 | 100 | 25.0 | |||
| Piperacillin-tazobactam | 81.8 | 75.0 | 85.7 | 0 | |||
| Meropenem | 85.5 | 0 | 0 | 50.0 | |||
| Levofloxacin | 85.5 | 50.0 | 57.1 | 50.0 | |||
| Amikacin | 98.2 | 87.5 | 100 | 75.0 | |||
| Colistin | NA | NA | NA | NA | |||
| Dominican Republic | (64) | (5) | (4)d | (2) | |||
| Ceftazidime-avibactam | 98.4 | 80.0 | 100 | 50.0 | |||
| Ceftazidime | 93.8 | 60.0 | 75.0 | 0 | |||
| Cefepime | 96.9 | 60.0 | 75.0 | 0 | |||
| Piperacillin-tazobactam | 96.9 | 60.0 | 75.0 | 0 | |||
| Meropenem | 92.2 | 0 | 0 | 0 | |||
| Levofloxacin | 78.1 | 60.0 | 75.0 | 0 | |||
| Amikacin | 87.5 | 80.0 | 100 | 50.0 | |||
| Colistin | NA | NA | NA | NA | |||
| Guatemala | (149) | (42) | (26)e | (33) | |||
| Ceftazidime-avibactam | 90.6 | 66.7 | 100 | 57.6 | |||
| Ceftazidime | 75.8 | 38.1 | 57.7 | 18.2 | |||
| Cefepime | 73.8 | 23.8 | 38.5 | 0 | |||
| Piperacillin-tazobactam | 71.8 | 21.4 | 34.6 | 0 | |||
| Meropenem | 71.8 | 0 | 0 | 6.1 | |||
| Levofloxacin | 70.5 | 16.7 | 23.1 | 3.0 | |||
| Amikacin | 79.2 | 33.3 | 50.0 | 15.2 | |||
| Colistin | NA | NA | NA | NA | |||
| Mexico | (562) | (238) | (29) | (160) | (167) | ||
| Ceftazidime-avibactam | 80.2 | 55.0 | 10.3 | 79.4 | 38.9 | ||
| Ceftazidime | 64.4 | 32.8 | 3.4 | 48.1 | 9.6 | ||
| Cefepime | 65.7 | 31.5 | 6.9 | 44.4 | 9.0 | ||
| Piperacillin-tazobactam | 64.1 | 31.1 | 3.4 | 43.1 | 8.4 | ||
| Meropenem | 57.7 | 0 | 0 | 0 | 3.6 | ||
| Levofloxacin | 59.3 | 23.9 | 3.4 | 33.8 | 7.2 | ||
| Amikacin | 74.6 | 42.9 | 3.4 | 56.9 | 25.7 | ||
| Colistin | NA | NA | NA | NA | NA | ||
| Panama | (80) | (21) | (13)f | (11) | |||
| Ceftazidime-avibactam | 87.5 | 52.4 | 84.6 | 36.4 | |||
| Ceftazidime | 82.5 | 38.1 | 61.5 | 18.2 | |||
| Cefepime | 82.5 | 38.1 | 61.5 | 9.1 | |||
| Piperacillin-tazobactam | 77.5 | 28.6 | 46.2 | 9.1 | |||
| Meropenem | 73.8 | 0 | 0 | 9.1 | |||
| Levofloxacin | 63.7 | 23.8 | 38.5 | 9.1 | |||
| Amikacin | 88.8 | 57.1 | 92.3 | 45.5 | |||
| Colistin | NA | NA | NA | NA | |||
| Venezuela | (237) | (77) | (23)g | (62) | |||
| Ceftazidime-avibactam | 75.9 | 26.0 | 73.9 | 12.9 | |||
| Ceftazidime | 71.3 | 18.2 | 56.5 | 4.8 | |||
| Cefepime | 71.7 | 18.2 | 43.5 | 4.8 | |||
| Piperacillin-tazobactam | 69.6 | 16.9 | 47.8 | 3.2 | |||
| Meropenem | 67.5 | 0 | 0 | 0 | |||
| Levofloxacin | 53.2 | 3.9 | 8.7 | 1.6 | |||
| Amikacin | 74.3 | 23.4 | 60.9 | 8.1 | |||
| Colistin | NA | NA | NA | NA | |||
Abbreviations: NS, non-susceptible; MBL-, no gene encoding a metallo-β-lactamase was detected by PCR; carbapenemase+/-, a gene encoding a serine carbapenemase was (+) or was not (-) detected by PCR; multidrug-resistant, isolates resistant to three or more sentinel agents from different drug classes; NA, no breakpoint available.
Composed of 2 carbapenemase-positive and 78 carbapenemase-negative isolates.
Composed of 5 carbapenemase-positive and 104 carbapenemase-negative isolates.
Composed of 7 carbapenemase-negative isolates.
Composed of 4 carbapenemase-negative isolates.
Composed of 2 carbapenemase-positive and 24 carbapenemase-negative isolates.
Composed of 13 carbapenemase-negative isolates.
Composed of 23 carbapenemase-negative isolates.